ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2602

Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

Gaetane Nocturne1,2, Bineta Ly3, Saida Boudaoud4, raphaèle seror5,6, Laurence Zitvogel7 and Xavier Mariette8,9, 1Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 2INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, 3INSERM U1184, Paris Sud University, Kremlin Bicetre, France, 4INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, 5Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, 6INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, 7IGR - INSERM U1015, Villejuif, France, 8Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, 9INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, Natural killer (NK) cells and rheumatoid arthritis (RA)

Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce an additional risk. Since, NK cells have been recently shown to participate to anti–lymphoma immunosurveillance, we aimed to assess if anti-TNF might impact their anti-lymphoma activity.

Methods:

NK cells have been assessed ex vivo in patients with RA treated with methotrexate (MTX) with (n=19) or without (n=20) anti-TNF. Phenotype has been studied by flow cytometry and function (degranulation and IFNg production) has been assessed after NKp30-cross linking. Then, we have studied the consequences of in vitro exposure of NK to anti-TNF, to TNF-R inhibitors or to controls during 6 days: phenotype has been studied and then cytotoxicity against 2 B non-Hodgkin lymphoma cell lines [Farage (EBV+) and SU-DHL4 (EBV-)] was assessed.

Results are shown as median [interquartile range (IGR)]. The Mann Whitney test was used to compare independent samples.

Results:

Firstly, in patients, we found that the proportion of activated NK cells, assessed by the expression of CD69, was significantly decreased in patients treated with anti-TNF + MTX compared to patients treated with MTX alone (8.9% [2.9 – 40.7] vs 48.4% [27.4 – 58.3], p=0.005). Moreover, we found that NK cells exhibited an impaired function in patients treated with anti-TNF compared to patients treated with MTX alone as assessed by the percentage of degranulation (20.9% [18.5 – 32.9] vs 31.3% [21.5 – 49.1], p=0.04) and the loss of capacity of IFN-γ secretion ((17.4% [8.9 – 25.9] vs to 29.7% [22.5 – 43.1], p=0.007). Secondly, we have confirmed that in vitro exposure to anti-TNF negatively impact NK cells activation and function leading to an impaired anti-lymphoma activity (figure 1A). In all these experiments, no difference was observed between etanercept and monoclonal anti-TNF. Last, we have demonstrated that negative impact of anti-TNF on NK cells may be the consequence of inhibition of TNF-R1 signaling (figure 1B).

Conclusion:

Even if meta-analysis of randomized controlled trials and of registries have not demonstrated to date an increased risk of lymphoma with anti-TNF, cautious must be pursued concerning this possible side effect in patients with long-term exposure. Moreover, negative impact of anti-TNF on NK cells may participate to infectious adverse events.

Description: C:\Users\3206627\Desktop\figure.jpg

 


Disclosure: G. Nocturne, None; B. Ly, None; S. Boudaoud, None; R. seror, None; L. Zitvogel, None; X. Mariette, None.

To cite this abstract in AMA style:

Nocturne G, Ly B, Boudaoud S, seror R, Zitvogel L, Mariette X. Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-tnf-therapy-is-associated-with-an-impaired-function-of-nk-cells-and-a-defective-immunosurveillance-against-b-cell-lymphomas/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tnf-therapy-is-associated-with-an-impaired-function-of-nk-cells-and-a-defective-immunosurveillance-against-b-cell-lymphomas/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology